Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025

Viewing 1-20 of 24 articles

APCCC Diagnostics 2025: How Do You Translate Next-Generation Imaging to Conventional Imaging for Treatment Decisions?

APCCC Diagnostics 2025: What Imaging Should You Use in Case of Suspected Metastases?

APCCC Diagnostics 2025: Prognostic, Predictive and Response Biomarkers during PSMA RLT

APCCC Diagnostics 2025: Monitoring of Patients on PSMA-Radioligand Therapy

APCCC Diagnostics 2025: What to Do in Non-Responding PSMA RLT Patients?

APCCC Diagnostics 2025: What Do You Want to Have Reported in MRI and PSMA PET?

APCCC Diagnostics 2025: Metastatic Disease: Monitoring with Whole Body MRI

APCCC Diagnostics 2025: When to Assess Biology with ctDNA?

APCCC Diagnostics 2025: False Positive PSMA PET: What to Know?

APCCC Diagnostics 2025: What Can MRI Contribute in Biochemical Recurrence?

APCCC Diagnostics 2025: Genomic Classifiers at the Time of Biochemical Recurrence

APCCC Diagnostics 2025: When to Assess Biology with a Re-Biopsy?

APCCC Diagnostics 2025: What Do We Expect from Monitoring in Metastatic Prostate Cancer?

APCCC Diagnostics 2025: PSA Relapse: When Do You Need to Act?

APCCC Diagnostics 2025: What Clinicians Need to Know from the PSMA RLT Selection PET?

APCCC Diagnostics 2025: What Do You Do with a Negative Scan: Treat Now or Later with a Positive Scan?

APCCC Diagnostics 2025: Biochemical Recurrence: When Do You Image?

APCCC Diagnostics 2025: PCWG4 and SPARC - Including How to Define Progression on PSMA PET Imaging

APCCC Diagnostics 2025: New Fashion Blood Markers for Metastatic Prostate Cancer

APCCC Diagnostics 2025: You Need Next Generation Imaging and It Must Be PSMA PET

1
2